Department of Medicine, Johns Hopkins University School of Medicine, 1830 Building Room 450B, 1830 East Monument Street, Baltimore, MD 21287, USA.
Department of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Osler 527, Baltimore, MD, USA.
Clin Chest Med. 2019 Dec;40(4):811-827. doi: 10.1016/j.ccm.2019.08.001.
Tuberculosis (TB) has now surpassed HIV as the leading infectious cause of death, and treatment success rates are declining. Multidrug-resistant TB, extensively drug-resistant TB, and even totally drug-resistant TB threaten to further destabilize disease control efforts. The second wave in TB drug development, which includes the diarylquinoline, bedaquiline, and the nitroimidazoles delamanid and pretomanid, may offer options for simpler, shorter, and potentially all-oral regimens to treat drug-resistant TB. The "third wave" of TB drug development includes numerous promising compounds, including less toxic versions of older drug classes and candidates with novel mechanisms of action.
结核病（TB）现已超过艾滋病毒，成为导致死亡的主要传染病，且治疗成功率正在下降。耐多药结核病、广泛耐药结核病，甚至完全耐药结核病有可能进一步破坏疾病控制工作。TB 药物研发的第二波浪潮包括二芳基喹啉、贝达喹啉以及硝基咪唑类药物德拉马尼和普雷托马尼，它们可能为治疗耐药性结核病提供更简单、更短、且可能全口服的方案选择。TB 药物研发的“第三波浪潮”包括许多有前途的化合物，包括毒性较小的旧药类别和具有新型作用机制的候选药物。
